# A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

> **NCT00245362** · PHASE2 · COMPLETED · sponsor: **Cell Genesys** · enrollment: 50 (—)

## Conditions studied

- Metastatic Pancreatic Cancer
- Nonresectable Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** CG 8020 and CG 2505

## Key facts

- **NCT ID:** NCT00245362
- **Lead sponsor:** Cell Genesys
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00245362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00245362, "A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00245362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*